Tesamorelin Bali
Frequently Asked Questions About Tesamorelin
Answers about how Tesamorelin works, what the published evidence shows, and how to check the labelled 32 mg pen in Bali.
Order on WhatsAppAbout the product and the evidence
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone. It stimulates the pituitary to release growth hormone made by the body. Researchers studied its effect on excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The original trial used CT scans to measure that fat compartment.
How does Tesamorelin work?
Tesamorelin activates GHRH receptors in the pituitary gland. This triggers growth hormone release, which in turn increases production of IGF-1 and influences fat metabolism. In clinical trials, researchers linked changes in this pathway to changes in visceral adipose tissue measured with imaging.
Is Tesamorelin a growth hormone?
No. Tesamorelin acts as the signal that prompts the pituitary gland to release its own growth hormone. Human growth hormone is a different molecule. This distinction matters because tesamorelin relies on a functioning pituitary growth hormone pathway.
What is visceral fat?
Visceral fat lies deep inside the abdominal cavity, around organs. Subcutaneous fat sits under the skin. A waist measurement includes both, while a CT scan lets researchers measure the visceral compartment separately. That is the measurement reported in the tesamorelin trials.
Does Tesamorelin reduce belly fat?
“Belly fat” can refer to more than one tissue. In the 2007 randomized trial, adults with HIV and abdominal fat accumulation had less visceral fat on CT after 26 weeks of tesamorelin. This result does not establish a benefit for cosmetic fat reduction or for subcutaneous fat in people without that condition.
Does Tesamorelin help with weight loss?
The US Egrifta WR label describes a weight-neutral effect and does not authorize general weight-loss treatment. The pivotal trial’s 15.2% reduction concerned the area of visceral fat on a CT image. Multiplying a person’s body weight by that percentage would give a misleading result.
What is the difference between Tesamorelin and Tirzepatide?
Tesamorelin activates the pituitary growth hormone–releasing hormone pathway. Its established US indication concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Tirzepatide acts on the GIP and GLP-1 receptors. Its obesity trials measured percentage change in total body weight, and specific tirzepatide products have approvals for weight management and type 2 diabetes.
What is the difference between Tesamorelin and Retatrutide?
Tesamorelin influences growth hormone release and has an established, formulation-specific indication in adults with HIV-associated lipodystrophy. Retatrutide is an investigational agonist at GLP-1, GIP, and glucagon receptors. Its obesity trials examined body weight. A percentage change in visceral fat in the tesamorelin trial cannot be compared directly with a percentage change in total weight.
What are the known side effects of Tesamorelin?
The US label lists injection-site reactions, joint pain, muscle pain, and fluid retention. Tesamorelin can raise IGF-1 and affect blood glucose. The prescribing information also explains precautions around malignancy and contraindications including pregnancy and disruption of the pituitary axis. Those safety data relate to the labeled prescription formulation.
Is Tesamorelin FDA-approved?
FDA approved specific Egrifta formulations for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The approved indication excludes general weight management. The Egrifta WR label describes a vial formulation. It does not identify the Body Pharm 32 mg prefilled pen as an approved product.
What does 32 mg mean on the pen label?
The number refers to the total stated amount of tesamorelin in the entire Body Pharm pen. It identifies the catalog format. It does not give an individual dose, the quantity dispensed by a selector setting, or the number of days it would last.
How should Tesamorelin be stored?
Body Pharm’s certificate for the 32 mg pen identifies lot C-TM32-3.0-20260228. It specifies a sealed container in a dark place at 2–8°C and says to avoid freezing. Check the instructions for the lot supplied. Other tesamorelin formulations, including prescription vials, have their own storage conditions.
Where can I read Tesamorelin clinical studies?
The references include the original 26-week trial by Falutz and colleagues, its 52-week extension, a second phase 3 trial, and the liver-fat trial by Stanley and colleagues. The original trial is also registered as NCT00123253. Each reference identifies the population, measurement, and follow-up period.
Ask the Bali team
Tell us how many Tesamorelin pens you want and where in Bali you are staying. We can confirm availability, the delivered price and a time that works for you.